VERITY: Value and Evidence in Rheumatology using bioInformaTics, and advanced analYtics
VERITY: Value and Evidence in Rheumatology using bioInformaTics, and advanced analYtics
批准号:
10251973
负责人:
Daniel Hal Solomon
金额:
$88.87万
依托单位国家:
美国
项目类别:
财政年份:
2017
资助国家:
美国
项目状态:
已结题
起止时间:
2017-09-20 至 2022-09-15
关键词:
ARHGEF5 geneAccountabilityAddressAdherenceAdultAffectAlgorithmsAmericasAreaArthritisBehavior TherapyBig DataBioinformaticsBiological MarkersBiosensorBody Weight decreasedChildhoodClinicalClinical InvestigatorClinical ResearchClinical Trials DesignCommunitiesComparative Effectiveness ResearchComputerized Medical RecordCountryDataData CollectionDatabasesDevelopmentDiseaseEvolutionFacultyFeedsFoundationsFundingFutureGenerationsGoalsGrantHarvestHealth TechnologyHospitalsInfrastructureInternationalInterventionKnowledgeLearningLongevityLupusMeasurableMentorsMethodologyMethodsMissionModelingMusculoskeletal DiseasesNational Institute of Arthritis and Musculoskeletal and Skin DiseasesNatural Language ProcessingOutcomeOutcome MeasureParticipantPatient CarePatient-Focused OutcomesPatientsPharmaceutical PreparationsPhenotypePhysical activityPopulationProtocols documentationPsoriatic ArthritisRegistriesResearchResearch DesignResearch MethodologyResearch PersonnelResourcesRheumatismRheumatologyScienceSeedsServicesSocietiesSupervisionTechnologyTestingTrainingWomanWorkadvanced analyticsanalytical methodbehavioral economicsbioinformatics resourcecare outcomesclinical careclinical research sitecohortcomparative effectiveness analysiscomparative effectiveness studydesigndistributed dataimprovedinnovationinsurance claimsmHealthmedical schoolsmultidimensional datanext generationnoveloptimal treatmentspatient engagementpatient orientedpreventprogramsskillstooltranslational studytreatment strategy
中文摘要
项目摘要
儿童和成人风湿性和肌肉骨骼(MSK)疾病挑战临床研究人员:
它们影响整个生命周期的人群,影响广泛的以患者为中心的结局,
通常有多种治疗策略。如果处理得当,这些因素
改善患者护理和患者结局的巨大机会。的首要目标
布里格姆妇女医院(BWH)CCCR是促进方法科学的进步
支持NIAMS儿科和成人风湿性和肌肉骨骼(MSK)的临床研究
疾病任务。
VERITY是围绕中心科学主题组织的,可应用于多种风湿性关节炎和
MSK疾病。核心解决了以下交叉领域:1)包括临床试验中的患者
设计,结果选择,结果解释和传播; 2)整合行为经济学,
增强已知干预措施的益处,即,坚持药物治疗,参与体力活动,
减肥; 3)从大数据中提取最大信息量; 4)使用智能技术(移动的
健康),以促进临床研究;和5)传播知识和指导地方和国家
风湿病和MSK疾病的临床研究人员通过分布式学习模型。这些科学主题
将通过以下具体目标中描述的几个核心来实现。1.从战略上指导,
监督和向真理提供财务问责制,并培训一大批地方和国家
研究人员在儿童和成人风湿性和MSK疾病的患者为导向的临床研究。
(行政核心)2。在创新试验中开发和实施最先进的方法,
风湿性和MSK疾病研究的纵向比较有效性研究。(方法论核心)
3.支持生物信息学方法,以提高大型数据库的利用率,
患者,并实施生物标志物,电子病历和比较有效性分析。
(生物信息学资源核心)
英文摘要
PROJECT ABSTRACT
Pediatric and adult rheumatic and musculoskeletal (MSK) diseases challenge the clinical researcher:
they affect the population across the lifespan, impact a broad range of patient-centered outcomes, are rarely
cured, and often have multiple possible treatment strategies. If properly addressed, these factors present
tremendous opportunities for improving patient care and outcomes of patients. The overarching goal of the
Brigham and Women’s Hospital (BWH) CCCR is to facilitate advancements in the methodologic sciences
supporting clinical research within the NIAMS pediatric and adult rheumatic and musculoskeletal (MSK)
disease missions.
VERITY is organized around central scientific themes that can be applied to multiple rheumatic and
MSK diseases. The Cores address the following cross-cutting areas: 1) including patients in clinical trial
design, outcome selection, result interpretation, and dissemination; 2) integrating behavioral economics to
enhance benefits of known interventions, i.e., adherence to medications, engagement in physical activity and
weight loss; 3) extracting maximum information content from big data; 4) using smart technologies (mobile
health) to advance clinical research; and 5) disseminating knowledge and mentoring of local and national
rheumatic and MSK disease clinical researchers through distributed learning models. These scientific themes
will be approached through several Cores described in the following Specific Aims. 1. To strategically direct,
supervise, and provide financial accountability to VERITY and to train a broad group of local and national
investigators for patient-oriented clinical research in pediatric and adult rheumatic and MSK diseases.
(Administrative Core) 2. To develop and implement state of the art methods in innovative trials and
longitudinal comparative effectiveness studies for rheumatic and MSK disease research. (Methodology Core)
3. To support bioinformatic approaches to enhance utilization of large databases for phenotyping relevant
patients, and implementing biomarker, electronic medical record, and comparative effectiveness analyses.
(Bioinformatics Resource Core)
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Rheumatoid Arthritis and the Risk of Cardiovascular Disease: Biomarkers Risk Prediction and Underlying Mechanisms
-
批准号:10416473
-
项目类别:
-
资助金额:$68.32万
-
财政年份:2022
-
负责人:Daniel Hal Solomon
-
依托单位:
Rheumatoid Arthritis and the Risk of Cardiovascular Disease: Biomarkers Risk Prediction and Underlying Mechanisms
-
批准号:10643971
-
项目类别:
-
资助金额:$74.63万
-
财政年份:2022
-
负责人:Daniel Hal Solomon
-
依托单位:
VERITY: Value and Evidence in Rheumatology using bioInformaTics, and advanced analYtics
-
批准号:9768189
-
项目类别:
-
资助金额:$89.49万
-
财政年份:2017
-
负责人:Daniel Hal Solomon
-
依托单位:
VERITY: Value and Evidence in Rheumatology using bioInformaTics, and advanced analYtics
-
批准号:10017653
-
项目类别:
-
资助金额:$89.39万
-
财政年份:2017
-
负责人:Daniel Hal Solomon
-
依托单位:
VERITY: Value and Evidence in Rheumatology using bioInformaTics, and advanced analYtics
-
批准号:9413618
-
项目类别:
-
资助金额:$90.75万
-
财政年份:2017
-
负责人:Daniel Hal Solomon
-
依托单位:
VERITY: Value and Evidence in Rheumatology using bioInformaTics, and advanced analYtics
-
批准号:10705645
-
项目类别:
-
资助金额:$89.11万
-
财政年份:2017
-
负责人:Daniel Hal Solomon
-
依托单位:
Administrative Core
-
批准号:10705713
-
项目类别:
-
资助金额:$30.16万
-
财政年份:2017
-
负责人:Daniel Hal Solomon
-
依托单位:
Administrative Core
-
批准号:10251977
-
项目类别:
-
资助金额:$30.84万
-
财政年份:2017
-
负责人:Daniel Hal Solomon
-
依托单位:
Administrative Core
-
批准号:10017666
-
项目类别:
-
资助金额:$31.27万
-
财政年份:2017
-
负责人:Daniel Hal Solomon
-
依托单位:
Towards Evidence-Based Monitoring of Low Dose Methotrexate: CIRT Ancillary Study
-
批准号:9272426
-
项目类别:
-
资助金额:$84.03万
-
财政年份:2014
-
负责人:Daniel Hal Solomon
-
依托单位:
Towards Evidence-Based Monitoring of Low Dose Methotrexate: CIRT Ancillary Study
-
批准号:8760929
-
项目类别:
-
资助金额:$69.39万
-
财政年份:2014
-
负责人:Daniel Hal Solomon
-
依托单位:
Rheumatic expertise expanded access to improve community health REACH-RA
-
批准号:8293775
-
项目类别:
-
资助金额:$37.59万
-
财政年份:2012
-
负责人:Daniel Hal Solomon
-
依托单位:
Hydroxychloroquine to Improve Insulin Sensitivity in Rheumatoid Arthritis
-
批准号:8013621
-
项目类别:
-
资助金额:$20.57万
-
财政年份:2010
-
负责人:Daniel Hal Solomon
-
依托单位:
Hydroxychloroquine to Improve Insulin Sensitivity in Rheumatoid Arthritis
-
批准号:7774466
-
项目类别:
-
资助金额:$17.36万
-
财政年份:2010
-
负责人:Daniel Hal Solomon
-
依托单位:
Modifiable Disparities in Treatment for Rheumatoid Arthritis
-
批准号:7690625
-
项目类别:
-
资助金额:$36.3万
-
财政年份:2009
-
负责人:Daniel Hal Solomon
-
依托单位:
Osteonecrosis of the Jaw in Non-Cancer Patients Using Bisphosphonates
-
批准号:7659840
-
项目类别:
-
资助金额:$26.68万
-
财政年份:2009
-
负责人:Daniel Hal Solomon
-
依托单位:
Modifiable Disparities in Treatment for Rheumatoid Arthritis
-
批准号:8116558
-
项目类别:
-
资助金额:$58.48万
-
财政年份:2009
-
负责人:Daniel Hal Solomon
-
依托单位:
Modifiable Disparities in Treatment for Rheumatoid Arthritis
-
批准号:7891330
-
项目类别:
-
资助金额:$38.42万
-
财政年份:2009
-
负责人:Daniel Hal Solomon
-
依托单位:
Modifiable Disparities in Treatment for Rheumatoid Arthritis
-
批准号:8298604
-
项目类别:
-
资助金额:$58.34万
-
财政年份:2009
-
负责人:Daniel Hal Solomon
-
依托单位:
Estimating and Communicating Risk about Biologic DMARDs for Rheumatoid Arthritis
-
批准号:8278595
-
项目类别:
-
资助金额:$15.03万
-
财政年份:2008
-
负责人:Daniel Hal Solomon
-
依托单位:
海外基金